Your head is probably filling up with questions, so let us help answer them. Learn about Pompe disease, see what the road ahead may look like, and find support at CareConnectPSS®.
Considering a switch?
NEXVIAZYME is an enzyme replacement monotherapy* that’s proven to help people with LOPD breathe easier and walk farther. Learn how this #1 prescribed LOPD treatment† works and why it could be worth switching to.
*Not including pretreatment or premedication.
†Prescription data as of July 14, 2023.
Already on NEXVIAZYME?
With LOPD, you need personalized treatment and attention. As always, your CareConnectPSS® team is here to give you clear information, provide helpful tools and resources, and to be caring allies.
See how NEX moves people
Amy is a real LOPD patient. See why she chose NEXVIAZYME.
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Your doctor may decide to give you antihistamine, anti-fever and/or steroid medications before your infusions. Your doctor should consider the risks and benefits of restarting the infusion if you have a severe hypersensitivity reaction (including anaphylaxis) to NEXVIAZYME. If a mild or moderate hypersensitivity reaction occurs, your healthcare provider may slow the infusion rate or temporarily stop the infusion.
Infusion-Associated Reactions (IARs): See Boxed WARNING. Your doctor may decide to give you medications before your infusions to decrease the risk of IARs; however, IARs may still occur after receiving these medications. If mild or moderate IARs occur, your healthcare provider should consider decreasing the infusion rate or temporarily stopping the infusion which may help improve the symptoms.
Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.
The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.
NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].
Please see full Prescribing Information for complete details, including Boxed WARNING.